Schizophrenia
Conditions
Interventions
Sponsors
Department of Physiology,Yokohama City University, School of Medicie
Keio University Hospital,Kyusyu University Hospital,Fukui University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Fulfilling the criteria of schizophrenia according to Structured Clinical Interview for DSM-IV, SCID-I/DSM-IV,Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM5),and International Statistical Classification of Diseases and Related Health Problems 10th Revison(ICD-10) (2) Being capable of providing informed consent
Exclusion criteria
Exclusion criteria: (1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AMPA receptor density in the right middle temporal gyrus and right anterior cingulate gyrus and PANSS score | — |
Secondary
| Measure | Time frame |
|---|---|
| AMPA receptor density and scores in the following scales: Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), Autism-Spectrum Quotient (AQ), Post-traumatic Stress Diagnostic Scale (PDS), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS),Y-BOCS Adverse events during 7 days after administration of [11C]K-2 | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Eiro
Yokohama City University, School of Medicie Physiology
Outcome results
None listed